References:
  1. Castillo, Jorge J., and Steven P. Treon. “Initial Evaluation of the Patient with Waldenström Macroglobulinemia.”Hematology/Oncology Clinics of North America , vol. 32, no. 5, 2018, pp. 811–820., doi:10.1016/j.hoc.2018.05.008.
  2. Castillo, Jorge J., et al. “Recommendations for the Diagnosis and Initial Evaluation of Patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.” British Journal of Haematology , vol. 175, no. 1, May 2016, pp. 77–86., doi:10.1111/bjh.14196.
  3. Minnema, Monique C., et al. “Guideline for the Diagnosis, Treatment and Response Criteria for Bing-Neel Syndrome.” Haematologica , vol. 102, no. 1, June 2016, pp. 43–51., doi:10.3324/haematol.2016.147728.
  4. Swerdlow, Steven H., et al. “The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms.” Blood , vol. 127, no. 20, 2016, pp. 2375–2390., doi:10.1182/blood-2016-01-643569.
  5. Arjunan, Ananth, and Hema Rai. “Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing–Neel Syndrome.” Case Reports in Hematology , vol. 2019, 2019, pp. 1–3., doi:10.1155/2019/4075960.
  6. Kulkarni, Tushar, et al. “Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom’s Macroglobulinemia.” Blood , vol. 122, no. 21, 2013, pp. 5090–5090., doi:10.1182/blood.v122.21.5090.5090.
  7. Grainger, Brian T., and Samar Issa. “Bing-Neel Syndrome Presenting as Isolated CNS Lymphoplasmacytic Lymphoma: A Case Report and Review of the Literature.” Journal of Clinical Neuroscience , vol. 71, 2020, pp. 277–280., doi:10.1016/j.jocn.2019.11.013.
  8. Kopinska, Anna J., et al. “Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström’s Macroglobulinemia.” Turkish Journal of Hematology , Nov. 2017, pp. 186–187., doi:10.4274/tjh.2016.0452.
  9. Kim, Ho-Jung, et al. “Brain Magnetic Resolution Imaging to Diagnose Bing-Neel Syndrome.” Journal of Korean Neurosurgical Society , vol. 46, no. 6, 2009, p. 588., doi:10.3340/jkns.2009.46.6.588.
  10. Matsuda, Sakino, et al. “An Autopsy Case of Bing-Neel Syndrome: Discrepancy between the Radiological and Pathological Findings.”Internal Medicine , vol. 58, no. 13, Jan. 2019, pp. 1947–1951., doi:10.2169/internalmedicine.1907-18.
  11. Hiemcke-Jiwa, Laura S., et al. “The Use of Droplet Digital PCR in Liquid Biopsies: A Highly Sensitive Technique for MYD88 p.(L265P) Detection in Cerebrospinal Fluid.” Hematological Oncology , vol. 36, no. 2, June 2017, pp. 429–435., doi:10.1002/hon.2489.
  12. Poulain, Stéphanie, et al. “MYD88 L265P Mutation Contributes to the Diagnosis of Bing Neel Syndrome.” British Journal of Haematology, U.S. National Library of Medicine, Nov. 2014, www.ncbi.nlm.nih.gov/pubmed/25160558/.
  13. Castillo JJ et al. “How we manage Bing-Neel syndrome”. Br J Haematol . 2019;187(3):277–285. doi:10.1111/bjh.16167
  14. Vos, Josephine M.i., et al. “Effective Treatment of Bing-Neel Syndrome with Oral Fludarabine: a Case Series of Four Consecutive Patients.” British Journal of Haematology , vol. 172, no. 3, May 2015, pp. 461–464., doi:10.1111/bjh.13483.
  15. Delgado, Julio, et al. “Radiation Therapy and Combination of Cladribine, Cyclophosphamide, and Prednisone as Treatment of Bing-Neel Syndrome: Case Report and Review of the Literature.” American Journal of Hematology , vol. 69, no. 2, 2002, pp. 127–131., doi:10.1002/ajh.10023.
  16. Varettoni, Marzia, et al. “Successful Treatment with Rituximab and Bendamustine in a Patient with Newly Diagnosed Waldenströms Macroglobulinemia Complicated by Bing-Neel Syndrome.” American Journal of Hematology , vol. 90, no. 8, 2015, doi:10.1002/ajh.24059.
  17. Castillo, J., et al. “Ibrutinib For The Treatment Of Bing-Neel Syndrome: A Retrospective, Multicenter Study.” Hematological Oncology , vol. 37, 2019, pp. 183–184., doi:10.1002/hon.140_2629.
  18. Mason, Christopher, et al. “Ibrutinib Penetrates the Blood Brain Barrier and Shows Efficacy in the Therapy of Bing Neel Syndrome.”British Journal of Haematology , vol. 179, no. 2, 2016, pp. 339–341., doi:10.1111/bjh.14218.
  19. Hashmi, Hamza, et al. “Rare Case of Bing-Neel Syndrome Treated Successfully with Ibrutinib.” BMJ Case Reports , vol. 12, no. 6, 2019, doi:10.1136/bcr-2019-230067.
  20. Wong, Jonathan, et al. “Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome.” HemaSphere , 2018, p. 1., doi:10.1097/hs9.0000000000000155.
  21. Gavriatopoulou, Maria, et al. “Treatment of Bing–Neel Syndrome with First Line Sequential Chemoimmunotherapy.” Medicine , vol. 98, no. 44, 2019, doi:10.1097/md.0000000000017794.
  22. Fitsiori, A et al. ”Imaging spectrum of Bing–Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström’s macroglobulinemia?”. Eur Radiol  29, pp. 102–114 (2019). https://doi.org/10.1007/s00330-018-5543-7.
  23. Treon, Steven P., et al. “MYD88 L265P Somatic Mutation in Waldenström’s Macroglobulinemia”. N Engl J Med 2012. 367:826-833. DOI: 10.1056/NEJMoa1200710
  24. Ansell, S. et al. “ Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.” Blood Cancer Journal  4, e183 (2014). https://doi.org/10.1038/bcj.2014.4
  25. Dotta L., et al. “Clinical And Genetic Features Of Warts, Hypogammaglobulinemia, Infections And Myelokathexis (WHIM) Syndrome.”Curr Mol Med. 2011 Jun: 11(4):317-25.
  26. Cao, Y. et al, “CXCR4  WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 L265P‐directed survival signalling in Waldenström macroglobulinaemia cells”. Br J Haematol, 168: 701-707. doi:10.1111/bjh.13200
  27. Kalatsakaya, I. et al, “AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties.”Molecular Pharmacology  May 1, 2009, 75 (5) pp. 1240-1247; DOI: https://doi.org/10.1124/mol.108.053389
  28. McDermott, David H., et al. “Plerixafor For The Treatment Of WHIM Syndrome.”
N Engl J Med 2019; 380:163-170.DOI: 10.1056/NEJMoa1808575.